Key result
Perfluorocarbon-supplemented perfusate increases aortic output ~87% and reverses mitochondrial hypoxia in isolated working hearts.
Why the study?
The extent to which decreased myoglobin oxygen saturation limits oxidative phosphorylation and cardiac performance in crystalloid-perfused working hearts is unresolved.
Does supplementing Krebs-Henseleit perfusate with perfluorocarbon emulsion improve cardiac performance and mitochondrial oxygenation in isolated working hearts?
Does supplementing Krebs-Henseleit perfusate with perfluorocarbon emulsion improve cardiac performance and mitochondrial oxygenation in isolated working hearts?
Absolute Event Rate: 142% vs 76%
Supplementing crystalloid perfusate with oxygen-carrying perfluorocarbons reverses mitochondrial hypoxia and improves cardiac performance in isolated working heart models.
May limit OxPhos interpretation in crystalloid-perfused hearts; leaves open myoglobin saturation effects on mitochondrial function.
The left ventricular working, crystalloid-perfused heart is used extensively to evaluate basic cardiac function, pathophysiology, and pharmacology. Crystalloid-perfused hearts may be limited by oxygen delivery, as adding oxygen carriers increases myoglobin oxygenation and improves myocardial function. However, whether decreased myoglobin oxygen saturation impacts oxidative phosphorylation (OxPhos) is unresolved, since myoglobin has a much lower affinity for oxygen than cytochrome c oxidase (COX). In the present study, a laboratory-based synthesis of an affordable perfluorocarbon (PFC) emulsion was developed to increase perfusate oxygen carrying capacity without impeding optical absorbance assessments. In left ventricular working hearts, along with conventional measurements of cardiac function and metabolic rate, myoglobin oxygenation and cytochrome redox state were monitored using a novel transmural illumination approach. Hearts were perfused with Krebs-Henseleit (KH) or KH supplemented with PFC, increasing perfusate oxygen carrying capacity by 3.6-fold. In KH-perfused hearts, myoglobin was deoxygenated, consistent with cytoplasmic hypoxia, and the mitochondrial cytochromes, including COX, exhibited a high reduction state, consistent with OxPhos hypoxia. PFC perfusate increased aortic output from 76 ± 6 to 142 ± 4 ml/min and increased oxygen consumption while also increasing myoglobin oxygenation and oxidizing the mitochondrial cytochromes. These results are consistent with limited delivery of oxygen to OxPhos resulting in an adapted lower cardiac performance with KH. Consistent with this, PFCs increased myocardial oxygenation, and cardiac work was higher over a wider range of perfusate Po2. In summary, heart mitochondria are limited by oxygen delivery with KH; supplementation of KH with PFC reverses mitochondrial hypoxia and improves cardiac performance, creating a more physiological tissue oxygen delivery. NEW & NOTEWORTHY Optical absorbance spectroscopy of intrinsic chromophores reveals that the commonly used crystalloid-perfused working heart is oxygen limited for oxidative phosphorylation and associated cardiac work. Oxygen-carrying perfluorocarbons increase myocardial oxygen delivery and improve cardiac function, providing a more physiological mitochondrial redox state and emphasizing cardiac work is modulated by myocardial oxygen delivery.
No takes yet. Share an insight, caveat, or question.
Kuzmiak‐Glancy et al. (2017) studied isolated working heart. perfluorocarbon (PFC) emulsion vs. Krebs-Henseleit (KH) alone was evaluated on aortic output. Supplementing Krebs-Henseleit perfusate with perfluorocarbon increased aortic output from 76 to 142 ml/min and reversed mitochondrial hypoxia in isolated working hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: